How to optimise anaemia therapy in peritoneal dialysis patients

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 202-213

  Macdougall, Iain C ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; DRUG EFFECT; ERYTHROPOIESIS; HUMAN; PERITONEAL DIALYSIS; PERITONITIS; REVIEW;

ANEMIA; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; IRON; PERITONEAL DIALYSIS; PERITONITIS;

EID: 33745266130     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093596     Document Type: Review

References (29)

1. Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504-510.
2. Pereira BJ: New perspectives in chronic renal insufficiency. Am J Kidney Dis 2000;36(suppl 3):S1-S3.
3. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, Horl WH, Macdougall IC, Macleod A, Wiecek A, Cameron S, European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
4. K/DOQI Anemia Guidelines in CKD patients. Am J Kidney Dis 2006; in press.
5. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996;27:347-354.
6. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990;300:573-578.
7. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000;11:335-342.
8. World Health Orgainzation. Nutritional Anaemias; Report of a WHO Scientific Group. World Geneva, Switzerland, Health Organization's, 1968.
9. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-1178.
10. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
11. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990;335:489-493.
12. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
13. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG: A randomized controlled trial of haemoglobin normalization with epoetin α in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003;18:353-361.
14. Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, Coyle D, Fine A, Handa P, Kingma I, Lau CY, Levin A, Mendelssohn D, Muirhead N, Murphy B, Plante RK, Posen G, Wells GA: Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000;58:1325-1335.
15. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005;16:2180-2189.
16. Locatelli F, Del Vecchio L: Dialysis adequacy and response to erythropoietic agents: what is the evidence base? Nephrol Dial Transplant 2003;18(suppl 8):viii29-viii35.
17. Macdougall IC: Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 1994;3:620-625.
18. Charytan C, Qunibi W, Bailie GR; Venofer Clinical Studies Group. Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005;100:c55-c62.
19. Fishbane S, Frei GL, Maesaka J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995;26:41-46.
20. Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
21. St Peter WL, Lambrecht LJ, Macres M: Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:523-528.
22. Macdougall IC, Roche A: Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections. Am J Kidney Dis 2005;46:283-289.
23. Fishbane S: Iron treatment: impact of safety issues. Am J Kidney Dis 1998;32(suppl 4):S152-S156.
24. Hoen B, Paul-Dauphin A, Hestin D, Kessler M: EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998;9:869-876.
25. Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623-1632.
26. Choukroun G, Gelu-Mantoulet S, Rouanet S, De Chasteigner A, Montestruc F, Berthoux F: Pain at the injection site: results of the first crossover study comparing epoetin beta and darbepoetin α administered subcutaneously in healthy volunteers. Nephrol Dial Transplant 2005;20(suppl 5):v262.
27. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD: Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989;1:425-427.
28. Macdougall IC: Hyporesponsiveness to anemia therapy - what are we doing wrong? Perit Dial Int 2001;21(suppl 3):S225-S230.
29. Macdougall IC: The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999;14:1836-1841.